---
title: "HUTCHMED pre-market fell over 2%, Morgan Stanley initiated a \"Sell\" rating"
description: "HUTCHMED pre-market fell 2.58%, reported at $16.6. In terms of news, Morgan Stanley analyst Jack Lin initiated a \"Sell\" rating on HUTCHMED, with a target price of $13.75"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/258318904.md"
published_at: "2025-09-22T09:43:21.000Z"
---

# HUTCHMED pre-market fell over 2%, Morgan Stanley initiated a "Sell" rating

> HUTCHMED pre-market fell 2.58%, reported at $16.6. In terms of news, Morgan Stanley analyst Jack Lin initiated a "Sell" rating on HUTCHMED, with a target price of $13.75

HUTCHMED pre-market fell 2.58% to $16.60. On the news, Morgan Stanley analyst Jack Lin initiated a "Sell" rating on HUTCHMED with a target price of $13.75

### Related Stocks

- [HCM.US - Hutchmed China](https://longbridge.com/en/quote/HCM.US.md)
- [00013.HK - HUTCHMED](https://longbridge.com/en/quote/00013.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hutchmed China hails lung cancer trial results published in Lancet | Hutchmed China Ltd announced that results from its SACHI phase-three lung cancer trial have been published in The Lancet | [Link](https://longbridge.com/en/news/272549848.md) |
| HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event | - HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanis | [Link](https://longbridge.com/en/news/263921874.md) |
| Anthropic: Investors in round include Insight Partners, Jane Street, JPMorganChase through Security & Resiliency Initiative & Growth Equity Partners | Anthropic: Investors in round include Insight Partners, Jane Street, JPMorganChase through Security & Resiliency Initiat | [Link](https://longbridge.com/en/news/275799043.md) |
| West Pharmaceutical Services Margins Slip To 16.3% Raising Questions Around Bullish Growth Narratives | West Pharmaceutical Services reported Q3 FY 2025 revenue of $804.6 million and EPS of $1.94, showing a revenue increase  | [Link](https://longbridge.com/en/news/275848079.md) |
| These Analysts Increase Their Forecasts On Equinix Following Q4 Results | Equinix Inc (NASDAQ:EQIX) reported strong Q4 results with FFO of $8.91 per share, exceeding estimates. However, quarterl | [Link](https://longbridge.com/en/news/275783781.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.